Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Jo Pisani takes a look at the different types of collaborations within the pharma industry, between pharma, biotech, academia and not-for-profit organisations. The biotech and pharma industries have each been struggling to translate the discoveries of the past decade into…

Articles

A plea to pharma to campaign for transparency: interview wit...

Dr Ben Goldacre shares his views on publication bias in the pharmaceutical industry and invites individuals from within pharma to get in touch and collaborate with him in trying to address this problem. Dr Ben Goldacre is a best-selling author, broadcaster, medical doctor and academic who specialises in...

Articles

Time to put Pharma 3.0 into action!

Phil Golz shares with pharmaphorum around why he would like to see less talk and more action around moving into the era of Pharma 3.0. Phil Golz works within GSK to identify existing and future areas of focus for pharmaceutical innovation. He speaks with pharmaphorum...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital